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The World Health Organization has called obesity a global epidemic. There is a strong
association between body weight gain and blood pressure. A major determinant of blood
pressure is the level of activity in sympathetic nerves innervating cardiovascular organs.
A characteristic of obesity, in both humans and in animal models, is an increase in
sympathetic nerve activity to the skeletal muscle vasculature and to the kidneys. Obesity
is now recognized as a chronic, low level inflammatory condition, and pro-inflammatory
cytokines are elevated including those produced by adipose tissue. Themost well-known
adipokine released from fat tissue is leptin. The adipokine, resistin, is also released
from adipose tissue. Resistin can act in the central nervous system to influence the
sympathetic nerve activity. Here, we review the effects of resistin on sympathetic nerve
activity and compare them with leptin. We build an argument that resistin and leptin may
have complex interactions. Firstly, they may augment each other as both are excitatory on
sympathetic nerves innervating cardiovascular organs; In contrast, they could antagonize
each other’s actions on brown adipose tissue, a key metabolic organ. These interactions
may be important in conditions in which leptin and resistin are elevated, such as in obesity.
Keywords: energy metabolism, resistin, leptin, sympathetic nerve activity, thermogenesis, brown adipose tissue,
cardiovascular function
INTRODUCTION
The worldwide increase in obesity is so dramatic that the World Health Organization has called
obesity a global epidemic. In 2014, more than 1.9 billion adults, 18 years and older, were
overweight (39%), and approximately 13% of the world’s adult population were obese (WHO,
2015). Disconcertingly, the worldwide prevalence of obesity more than doubled between 1980
and 2014 (WHO, 2015). There is a close, strong association between body weight gain and blood
pressure, which is similar for men and women and across age groups (Garrison et al., 1987; Hall
et al., 2002; Wofford and Hall, 2004). Therefore, obesity and the metabolic syndrome increase the
risk of cardiovascular disease and hypertension, and it is not surprising that with excess body weight
there is increased risk of long term health consequences and a substantial increase in mortality and
morbidity (WHO, 2014).
A major determinant of blood pressure is the level of activity in sympathetic nerves innervating
cardiovascular organs. A characteristic of obesity, in both humans (Grassi et al., 1998; Esler et al.,
2006) and in animalmodels (e.g., dogs, rats, and rabbits), is an increase in sympathetic nerve activity
to the skeletal muscle vasculature and to the kidneys (Levin et al., 1983; Kassab et al., 1995; Prior
et al., 2010). Renal sympathetic nerve activity is particularly important since it affects salt and water
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balance directly and indirectly by influencing renin release from
the kidney (hence activation of the renin angiotensin-aldosterone
system). The regulation of renal function by the sympathetic
nerves is a key player in obesity induced hypertension as
evidenced by the observations in obese dogs in which destruction
of the nerves projecting to the kidneys prevents both sodium
retention and the hypertension present in that model of obesity
(Kassab et al., 1995). The causes of the elevated sympathetic nerve
activity observed in obesity are unknown.
Obesity is now recognized as a chronic, low level
inflammatory condition. Pro-inflammatory cytokines are
elevated in obesity (Gregor and Hotamisligil, 2011) including
those produced by adipose tissue, either by the fat cells or the
macrophages that infiltrate the fat tissue, and are known as
adipokines. The most well-known adipokine released from fat
tissue is leptin. More recently, resistin, was also discovered as an
adipokine released from adipose tissue.
Here we review the effects of resistin on sympathetic nerve
activity and compare the effects to those of leptin, and discuss
their potential interactions that may contribute to cardiovascular
dysfunction.
RESISTIN
Resistin is a member of the resistin-like molecule (RELM)
hormone family. Two other members of the RELM family
include RELM-alpha and RELM-beta. All RELM family members
are characterized by 10 conserved cysteine residues. Resistin
and RELM-beta contain an additional cysteine near their amino
termini, which is conserved among species (Steppan et al., 2001;
Steppan and Lazar, 2002). Human and rodent resistin proteins
exhibit approximately 60% homology (Patel et al., 2004).
Resistin is secreted as a disulphide-linked homotrimer and
circulates in plasma as either the trimer or a hexamer (Ghosh
et al., 2003). The plasma levels of resistin are reported to be
approximately between 7 and 14 ng/ml in humans and 36–
43 ng/ml in rats (Azuma et al., 2003). In rodents, the main
source of resistin is white adipose tissue and expression may vary
between the different depots of adipose tissue and with gender
(Steppan et al., 2001). In contrast to rodents, the expression
of resistin in human adipocytes is low, and the main source
of resistin in humans is macrophages (Yang et al., 2003), and
in obesity, macrophages that have infiltrated into visceral white
adipose tissue are the predominant source of resistin (Curat et al.,
2006).
In addition to adipose tissue, resistin has also been detected
in a variety of other tissues in the periphery including adrenal
glands, skeletal muscle, kidney, and brown adipose tissue (BAT)
(Nohira et al., 2004). The physiological role of resistin in many of
these organs, however, is not clearly understood.
Resistin mRNA has been detected in the brain of rodents
suggesting that endogenous production of resistin can occur in
brain nuclei such as in the arcuate nucleus, ventromedial nucleus,
and hippocampus (Morash et al., 2002; Wilkinson et al., 2005). In
humans, resistin has been detected in cerebrospinal fluid, but the
levels do not appear to correlate with changes in plasma levels,
however, suggesting saturable uptake into the cerebrospinal fluid.
This is possibly by an active transport mechanism across the
blood brain barrier, as occurs with leptin. This, of course, does
not exclude local production of resistin in the brain.
Resistin levels in plasma are elevated in obesity and diabetes.
There are several studies in humans showing a positive
correlation between plasma resistin levels and increased body
mass index (Steppan et al., 2001; Azuma et al., 2003; Rajala et al.,
2004). Although, the majority of studies confirm the correlation
between resistin and obesity and Type 2 diabetes, a few reports
show resistin was not increased in patients with severe insulin
resistance and Type 2 diabetes (Janke et al., 2002).
Receptors for Resistin
It is surprising, perhaps, that a receptor for resistin has yet
to be unequivocally identified. Recent work has suggested
several candidates including a cleavage product of decorin (a
proteoglycan) that may be involved in growth of white adipose
tissue (Daquinag et al., 2011), adenyl cyclase associated protein-1
involved in mediating inflammatory processes in monocytes (Lee
et al., 2014), and toll like receptor 4 (Tarkowski et al., 2010).
RESISTIN AND SYMPATHETIC NERVE
ACTIVITY
Acute intracerebroventricular administration of resistin induces
a significant increase in lumbar sympathetic nerve activity in
rats (Figure 1; Kosari et al., 2011), a measure of sympathetic
nerve activity to the muscle vasculature. The effect was
centrally mediated since the same dose of resistin administered
intravenously failed to influence lumbar sympathetic nerve
activity (Kosari et al., 2011). In a separate study investigating
effects on the sympathetic outflow to the kidney in rats, resistin
was also found to increase renal sympathetic nerve activity
(Figure 2; Kosari et al., 2012). Since sympathetic nerve activity
to the muscle vasculature and to the kidneys is elevated in
obesity, metabolic syndrome, and diabetes (Grassi et al., 1998;
Esler et al., 2006; Zhang et al., 2012; Coats and Cruickshank,
2014; Thorp and Schlaich, 2015), the results raised the interesting
possibility that resistin may be a potential contributing factor to
the cardiovascular complications associated with those metabolic
conditions.
The doses of resistin utilized in reports in the literature
to elicit effects on sympathetic nerve activity needs some
comment. Studies have used microgram quantities administered
intracerebroventricularly (Tovar et al., 2005; Singhal et al.,
2007; Kosari et al., 2011, 2012, 2013) whilst, as noted above,
plasma levels are in the nanogram/ml range (Azuma et al.,
2003; Piestrzeniewicz et al., 2008; de Luis et al., 2009).
The reasons for this difference is not immediately apparent,
however, it is important to note that a similar issue is
observed for leptin. With leptin microgram quantities are
required intracerebroventricularly (Rahmouni et al., 2009a;
Prior et al., 2010; Harlan et al., 2013; Tanida et al., 2013) to
increase sympathetic nerve activity but plasma levels are in the
nanogram/ml range (Aizawa-Abe et al., 2000; Bryzgalova et al.,
2008; Lieb et al., 2009).
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FIGURE 1 | Top: Screen capture of the raw recordings of lumbar sympathetic
nerve activity (LSNA) and integrated lumbar SNA (ILSNA) before and after
resistin (7µg) administered into the lateral brain ventricle of an anesthetized
rat. x, horizontal bar = 2 s, vertical bar = 100mV (LSNA), and 10mV.s (ILSNA).
Lower: The percent changes in lumbar SNA from resting levels over 4 h
following resistin (7µg; n = 6) or control (artificial CSF; n = 7) administered into
the lateral brain ventricle of anesthetized rats. *p < 0.05 between groups
Two-way ANOVA. Modified from Kosari et al. (2011).
The intracellular mechanisms involved in the transduction of
the renal sympathetic nerve responses elicited by resistin have
been investigated. The increase in sympathetic nerve activity
to the kidney elicited by resistin was prevented by the central
administrations of the PI 3-kinase inhibitor LY294002 but was
not affected by inhibition of ERK1/2 indicating that PI 3-kinase
was an essential intracellular transduction pathway mediating
the central sympatho-excitatory actions of resistin (Kosari et al.,
2012; Figure 2). The central sites directly activated by resistin are
not yet clearly elucidated. However, studies using the protein,
Fos as a marker of increased neuronal activity, suggest the
paraventricular nucleus in the hypothalamus is a potential site
(Tovar et al., 2005; Singhal et al., 2007; Badoer, 2010; Kosari et al.,
2011). This nucleus plays a key role in renal sympathetic nerve
responses mediating body fluid regulation (Ng et al., 2004).
Interestingly, acute intracerebroventricular administration of
resistin did not significantly increase blood pressure (Kosari
et al., 2011). This would be understandable if resistin’s sympatho-
excitatory actions to the skeletal muscle vasculature and kidneys
were opposed by falls in sympathetic nerve activity to other
cardiovascular organs. This has not been directly investigated to
date. Alternatively, resistin may have direct sympatho-excitatory
and sympatho-inhibitory actions. Supporting this argument, we
have evidence that resistin does not elicit a generalized increase in
sympathetic nerve activity. In contrast to the excitatory actions
of resistin on lumbar and renal sympathetic nerve activities,
FIGURE 2 | Top: Screen capture of raw recordings of renal sympathetic nerve
activity (RSNA) and integrated renal SNA (IRSNA) before and after resistin
(7µg) administered into the lateral brain ventricle of an anesthetized rat. x,
horizontal bar = 2 s, vertical bar = 200mV (RSNA), and 10mV.s (IRSNA).
Modified from Kosari et al. (2012). Middle: Screen capture of raw recordings
of renal sympathetic nerve activity (RSNA) and integrated renal SNA (IRSNA)
before and after resistin (7µg) in the presence of the PI 3-Kinase inhibitor,
LY294002 (Ly) (5µg) administered into the lateral brain ventricle of an
anesthetized rat. x, horizontal bar = 2 s, vertical bar = 200mV (RSNA), and
10mV.s (IRSNA). Modified from Kosari et al. (2012). Lower: The percent
changes in renal sympathetic nerve activity (RSNA) from basal levels over time
following intracerebroventricular administration of saline (control) (n = 4) or
resistin (7µg) in the presence of LY294002, an inhibitor of PI3K (5µg, n = 5) or
vehicle (n = 7). *p < 0.05 between groups, Two-way ANOVA. Modified from
Kosari et al. (2012).
resistin, administered into the lateral cerebral ventricle of the
anesthetized rat induced, a reduction in sympathetic nerve
activity to brown adipose tissue (Kosari et al., 2011; Figure 3).
Brown adipose tissue is an important thermoregulatory organ.
In humans it was originally thought to be lost with age but it is
now known to be present and functionally active in adult humans
(Nedergaard et al., 2007). The data suggests resistin has inhibitory
actions on thermogenesis. Thus, resistin has differential effects on
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FIGURE 3 | Screen capture of raw recordings of brown adipose tissue
sympathetic nerve activity (BAT SNA) and integrated BAT SNA (IBAT
SNA) before, 2 and 4h after resistin (7µg) in the presence of vehicle or
ERK1/2 inhibitor (U0126, 7µg) (U) administered into the lateral brain
ventricle of anesthetized male rats. x, horizontal bar = 2 s, vertical bar =
200mV (BAT SNA), and 10mV.s (IBAT SNA). Modified from Kosari et al. (2012).
sympathetic outflow; excitatory to some organs and inhibitory on
others.
To date, studies investigating the effects of resistin on blood
pressure have studied the effects over short time frames (up to 4
h; Kosari et al., 2011, 2012). Whether, chronic administration of
resistin has effects on blood pressure and heart rate also needs to
be investigated, particularly since leptin has similar sympatho-
excitatory effects to resistin on lumbar and renal sympathetic
nerve activity (see later), and effects on blood pressure also differ
when acute and chronic administration of leptin are compared
(Beltowski, 2006). Since renal function is critical to chronic
blood pressure regulation, if the acute effects of resistin on renal
sympathetic nerve activity are maintained chronically, there may
indeed be long term effects that could lead to elevated blood
pressure in metabolic conditions in which resistin levels are
elevated.
The intracellular mechanisms that contribute to the central
effect of resistin on sympathetic nerve activity to brown adipose
tissue involves ERK 1/2 dependent pathways since the effects
are attenuated by the ERK 1/2 inhibitor U0126. Inhibition
of PI 3-kinase, however, had no effect on the sympatho-
inhibitory action of resistin (Kosari et al., 2012). Thus, the
intracellular transduction pathways in the brain mediating
the sympatho-excitatory and sympatho-inhibitory responses are
different.
Hypertension and Resistin
Since resistin was found to be sympatho-excitatory to key
cardiovascular tissues, one may have expected it to induce an
increase in blood pressure. As indicated earlier, this has not
been observed following acute administration of resistin in rats.
One possibility may be that resistin needs to be administered
chronically to observe increases in blood pressure. This has
not been investigated, however, several clinical studies have
shown that plasma resistin levels are associated with either
the presence or the development of high blood pressure in
humans. A positive correlation between plasma resistin levels and
hypertension, measured using 24 h ambulatory blood pressure
monitoring, has been observed (Papadopoulos et al., 2009;
Thomopoulos et al., 2010). Increased plasma resistin levels has
also been observed in a young healthy population with a family
history for essential hypertension (Papadopoulos et al., 2008).
This finding suggests that plasma resistin levels may have a
predictive value. This view has been supported by the findings
that plasma resistin levels were correlated with the risk of
developing hypertension over a 14 year follow up of 872 women
without previous history of hypertension or diabetes (Zhang
et al., 2010). Thus, the vast majority of studies have shown
a correlation between plasma resistin levels and hypertension
(Ellington et al., 2007; Takata et al., 2008; Dimitriadis et al.,
2009; Papadopoulos et al., 2009; Thomopoulos et al., 2010; Zhang
et al., 2010). By contrast only a few studies did not observe a
significant correlation (Furuhashi et al., 2003) or the correlation
was observed in patients with other risk factors present, such as
Type 2 diabetes, making the interpretation difficult (Asgary et al.,
2014).
LEPTIN
Leptin, discovered by Friedman and colleagues in 1994 (Zhang
et al., 1994), is the most investigated adipokine produced by the
adipose tissue. Leptin levels are increased in obesity in proportion
to fat mass and leptin is well-known to act in the central nervous
system to reduce food intake by regulating neuropeptides in the
hypothalamus; for example by reducing the activity of neurons
containing neuropeptide-Y (NPY) and agouti-related protein
(AgRP) and stimulating pro-opiomelanocortin (POMC)/cocaine
and amphetamine regulated transcript (CART) neurons in
the arcuate nucleus of the hypothalamus (Elias et al., 1998).
Considerable evidence indicates that leptin has also sympatho-
excitatory actions.
Leptin and Sympathetic Nerve Activity
Leptin administered acutely in the lateral cerebral ventricles
increases sympathetic nerve activity to the kidney, skeletal muscle
vasculature, splanchnic region, adrenal gland, and brown adipose
tissue (Dunbar et al., 1997; Haynes et al., 1997). Thus, leptin
appears to have a generalized action in increasing sympathetic
nerve activity. The sympatho-excitatory actions of leptin are
primarily mediated via the activation of receptors in the brain,
although recent evidence suggests that leptin can also activate
afferent nerve activity from white adipose tissue that results in
increased sympathetic nerve activity (Xiong et al., 2012).
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The mechanism of action and chemical mediators in the
brain that contribute to the increase in sympathetic nerve
activity induced by leptin have been investigated. Blockade
of melanocortin 3/4 receptors, histamine H1 receptors and
angiotensin 1A receptors have been found to attenuate or prevent
the actions of leptin (da Silva et al., 2004; Morrison, 2004;
Hilzendeger et al., 2012). These data suggest that leptin, in
addition to the activation of its own receptors, also activates
central pathways that utilize melanocyte stimulating hormone,
histamine, and angiotensin II and these participate in the ability
of leptin to increase sympathetic nerve activity.
The intracellular transduction pathways involved in the
sympatho-excitatory responses induced by leptin involve PI 3-
Kinase, ERK1/2, and MTORC1. However, the contributions of
each of these may depend on the central pathways utilized to
influence the specific end organs. The increase in sympathetic
nerve activity to the kidney involves activation of PI 3-kinase
(Rahmouni et al., 2003, 2009a), but this is not the case for
lumbar and adrenal sympathetic nerve activities. Furthermore,
sympathetic nerve activity subserving brown adipose tissue
involves ERK 1/2 (Rahmouni et al., 2009b). Thus, although
leptin appears to induce a generalized increase in sympathetic
nerve activity, there is a clear demonstration of different central
pathways utilized by leptin to elicit increases in sympathetic
nerve activity to different end organs. Whether, this involves
different neurons within the same brain nuclei and/or different
nuclei subserving different responses requires investigation.
The arcuate nucleus, containing POMC neurons, appears to
be important in both the metabolic, and sympathetic responses
to leptin. Increases in sympathetic nerve activity to the kidneys
and to brown adipose tissue can be elicited by leptin acting
in the arcuate nucleus (Rahmouni and Morgan, 2007; Harlan
et al., 2011). There is some evidence, however, that different
nuclei contribute to increases in sympathetic nerve activity to
different end organs. For example, the subfornical organ (SFO)
and nucleus tractus solitarius (NTS); the SFO is a forebrain
structure lining the anterior wall of the third ventricle and
lacks a blood brain barrier, making it accessible to systemic
leptin. Selective removal of leptin receptors from the SFO by
targeted microinjection into the SFO of adenovirus encoding
Cre-recombinase in ObR(flox/flox) mice prevented the increase
in renal sympathetic nerve activity but was without effect on
leptin-induced increases in sympathetic nerve activity supplying
brown adipose tissue (Young et al., 2013). Local injections of
leptin into the NTS increased renal but was without effect on
brown adipose tissue sympathetic nerve activities (Mark et al.,
2009). It should be noted, however, that indirect measures of
sympathetic nerve activity to brown adipose tissue, such as
core body temperature, has been reported to increase following
leptin administration into the fourth ventricle that overlies the
NTS (Skibicka and Grill, 2009). Receptors for leptin are also
found in other autonomic nuclei in the brain and activation
of these by leptin can induce increases in sympathetic nerve
activity. These nuclei include the rostral ventrolateral medulla,
dorsomedial, and ventromedial hypothalamus (Montanaro et al.,
2005). Interestingly, the dorsomedial hypothalamus appears
to be essential in mediating leptin’s response in sympathetic
nerve activity to brown adipose tissue without affecting renal
sympathetic nerve activity (Zhang et al., 2011). Nonetheless,
leptin receptors in the dorsomedial hypothalamus appear to
be important contributors to obesity-associated hypertension
(Simonds et al., 2014). Thus, leptin may act on several brain
nuclei to elicit its sympathetic nerve activity responses. Exactly,
how these inter-relate or are accessed and/or activated by
systemic leptin awaits further investigation. It appears, however,
that some nuclei are responsible for specific sympathetic outputs
whilst others may integrate several sympathetic outputs.
Leptin Sympathetic Nerve Activity and Obesity
The elevation in sympathetic nerve activity induced by leptin is
believed to contribute to obesity induced hypertension. Studies in
rodents and rabbits in which administration of leptin chronically
increased renal sympathetic nerve activity and blood pressure
and studies showing that the increased blood pressure induced
by a high fat diet was maintained by leptin strongly support
this view (Beltowski, 2006; Lim et al., 2013; Simonds and
Cowley, 2013; Prior et al., 2014). The role of leptin is further
strengthened by studies showing that in rodents that lack leptin
or its receptor do not become hypertensive when fed high fat
diets (Simonds et al., 2014). However, evidence in humans is not
so forthcoming, primarily due to the lack of studies specifically
designed to investigate this issue. In animals, although, acute
injection of leptin does not consistently raise blood pressure,
despite increasing sympathetic nerve activity, chronic infusion of
leptin does increase blood pressure via sympathetically mediated
changes (Beltowski, 2006). Such a response could account for
the sustained increases in blood pressure that can accompany
obesity. This was suggested by the early studies comparing obese
leptin deficient rodents which had lower blood pressure than
their lean controls (Mark et al., 1999), and by studies in which
infusion of leptin into obese animals lacking leptin raised blood
pressure (Aizawa-Abe et al., 2000). Thus, leptin appeared to be
an important contributor to hypertension that may accompany
obesity.
Genetically engineered obesity models, however, are quite
different from models of obesity induced by diet. Here too,
however, the evidence for a role of leptin in hypertension is
relatively strong in animal studies (Prior et al., 2010; Simonds
et al., 2014). Recent work in rabbits is particularly interesting
since it suggests that not only is leptin responsible for the
increased sympathetic nerve activity and hypertension observed
with high fat feeding, but that the effect can last even when the
high fat diet is removed and replaced with a normal diet which
restored plasma leptin levels back to normal (Armitage et al.,
2012). This suggests that leptin may initiate hypertension and
may contribute to changes that canmaintain high blood pressure.
Obesity and Leptin Sensitivity
It has been known for some time that the ability of leptin to
reduce food intake was sharply attenuated in obese conditions.
This attenuation of the anorectic actions of leptin are due to
decreased receptor sensitivity at sites that are critical to food
intake (Mitchell et al., 2009). Thus, in obesity the effects of leptin
on food intake are weaker than in the lean state and this provided
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an explanation as to why in obesity, food intake was not reduced
as expected given the markedly elevated plasma levels of leptin.
Interestingly, estimates from clinical studies have suggested
about half the correlation between blood pressure and body
weight can be attributed to the variance in leptin levels in humans
(Abramson et al., 2011). How could leptin be responsible for a
relatively large proportion of the obesity-induced hypertension?
Such a question was perplexing when the metabolic/dietary
effects of leptin were clearly attenuated in obese conditions.
One explanation is the concept of selective leptin resistance
introduced by Mark et al. (2002). Originally, this concept was
derived from observations in models of obesity, in which the
authors determined that the blood pressure responses elicited by
leptin were similar in obese and lean conditions which contrasted
with the different dietary intake responses elicited by leptin in
those conditions.
The original findings used renal sympathetic nerve activity
as the neural output to show that the sensitivity to leptin
was retained in obesity. Subsequent findings, however, showed
that the response in sympathetic nerve activity innervating
brown adipose tissue following leptin was attenuated in obese
compared to lean animals (Rahmouni et al., 2005). Such results
suggested that there was differential resistance to leptin’s actions
on sympathetic nerve activity in obesity. The resistance to
the effects of leptin on sympathetic nerve activity to brown
adipose tissue has been questioned recently in experiments
in which the increase in temperature of brown adipose
tissue in response to leptin (a indirect marker of sympathetic
nerve activity to that tissue) was not attenuated in diet-
induced obese mice compared to lean controls (Enriori et al.,
2011).
There is also evidence of differential selective resistance
between the renal sympathetic nerve activity and sympathetic
outflows to other cardiovascular organs. For example, in contrast
to the renal sympathetic nerve activity, the responses to leptin
in both lumbar and splanchnic sympathetic nerve activities
are attenuated in obese conditions compared to lean controls
(Rahmouni et al., 2005). However, since the kidneys are critical
organs involved in cardiovascular function and chronic blood
pressure maintenance, the resistance to attenuation of the renal
sympathetic nerve response elicited by leptin, in the obese
condition could make a critical contribution to obesity-induced
hypertension.
Comparison of the Effects of Leptin and
Resistin on Sympathetic Nerve Activity
Based on the data to date, leptin and resistin increase
sympathetic outflow to the renal and lumbar regions (Table 1).
The intracellular transduction pathways mediating the changes
in renal sympathetic nerve activity are similar in that both
utilize PI 3-Kinase. Whether, the same neurons are utilized
awaits investigation. The effect of resistin on brown adipose
tissue sympathetic nerve activity, however, is opposite to that
induced by leptin, indicating the two have opposing actions on
thermogenesis.
Given our discussion above on the importance of the
renal sympathetic nerve responses in the potential for leptin
to contribute to obesity-induced hypertension, the similar
sympatho-excitatory actions of resistin and leptin on renal
sympathetic nerve activity could assume greater significance. We
are currently exploring the possibility that leptin and resistin
could have enhanced actions on renal sympathetic nerve activity
when both adipokines are present. Additionally, it is not known
FIGURE 4 | Schematic representation of the effects of leptin and
resistin on sympathetic nerve activity (SNA) to cardiovascular organs.
In normal lean states, resistin, and leptin act in the brain to increase
sympathetic nerve activity to the kidney and skeletal muscle vasculature.
These may influence blood pressure. In the obese state, it is hypothesized that
the increased levels of leptin and resistin leads to enhanced levels of
sympathetic nerve firing to the kidney and skeletal muscle vasculature that
could contribute to obesity-induced hypertension.
TABLE 1 | Comparison of effects of resistin and leptin on blood pressure and sympathetic nerve activity (SNA) to different cardiovascular and
thermogenic outputs.
Output Resistin Species and references Leptin Species and references
Blood pressure No change Rat (Kosari et al., 2011, 2012) No change Rat (Beltowski, 2006)
↑ Rat (Dunbar et al., 1997; Beltowski, 2006)
Renal SNA ↑ Rat (Kosari et al., 2012) ↑ Rat (Dunbar et al., 1997; Haynes et al., 1997; Rahmouni et al., 2009a)
Rabbit (Prior et al., 2010)
Mice (Rahmouni et al., 2003)
Lumbar SNA ↑ Rat (Kosari et al., 2011) ↑ Rat (Dunbar et al., 1997)
Splanchnic SNA Unknown ↑ Rat (Haynes et al., 1997)
BAT SNA ↓ Rat (Kosari et al., 2013) ↑ Rat (Rahmouni et al., 2009b)
Arrow direction indicates increase or decrease.
Frontiers in Physiology | www.frontiersin.org 6 November 2015 | Volume 6 | Article 321
Badoer et al. Resistin and sympathetic nerve activity
FIGURE 5 | Schematic representation of the central effects of leptin
and resistin on sympathetic nerve activity (SNA) to brown adipose
tissue. This contributes to changes in energy expenditure. Leptin increases
SNA to brown adipose tissue resulting in increased thermogenesis and energy
expenditure. In contrast, resistin reduces SNA to brown adipose tissue
resulting in a reduction in thermogenesis. In obesity when leptin and resistin
levels are elevated, it is tempting to speculate that the interaction with resistin
could contribute to the reduced leptin effects observed on SNA to brown
adipose tissue.
whether the selective resistance to the responses of leptin on
renal sympathetic nerve activity observed in the obese condition,
also occurs with resistin. If this is the case, then this could be
significant with respect to obesity–induced hypertension, since
plasma levels of both adipokines are elevated in obesity.
Perspective
In the obese condition, there is an elevation in renal and skeletal
muscle sympathetic nerve activity, and the increase in muscle
sympathetic nerve activity has been found to correlate with the
amount of visceral fat tissue (Alvarez et al., 2002). The findings
that resistin and leptin increase renal and lumbar sympathetic
nerve activity, taken together with the reports that plasma levels
of leptin and resistin are elevated in obesity, suggests that resistin
and leptin could contribute to the sympathetic nerve activity
disturbances observed in obesity (Figure 4). Evidence that leptin
contributes to the elevated sympathetic nerve activity in obese
conditions supports such a contention but resistin’s role needs
to be investigated. Nonetheless, as both resistin and leptin are
elevated in obesity, and they each have sympatho-excitatory
actions on renal and lumbar sympathetic nerve activity, it is
quite possible that the effects on those outputs is exacerbated
when leptin and resistin are present together. An exacerbated
effect on renal sympathetic nerve activity could influence sodium
retention, renal haemodynamics, and long term regulation of
blood pressure, all of which are abnormally elevated in obesity.
Thus, we hypothesize that leptin and resistin, when present
in high concentrations, may act together and contribute to
obesity-induced hypertension and renal dysfunction. Further,
studies in animal models of obesity are needed to explore this
hypothesis.
In contrast to the similar sympatho-excitatory effects of
resistin and leptin on renal and lumbar sympathetic nerve
activity, resistin reduces, whilst leptin increases, sympathetic
nerve activity innervating brown adipose tissue. The contrasting
actions on thermogenesis suggests resistin could blunt leptin’s
action on this metabolic output (Figure 5). Support for this
idea has recently been found in a study from Scherer’s group
(Asterholm et al., 2014). Based on the findings, it is tempting
to speculate that an interaction with resistin could contribute
to the selective leptin resistance observed on sympathetic
nerve activity to the kidney but not to brown adipose
tissue.
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